Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2017 Dec 6;17(1):141.
doi: 10.1186/s12876-017-0705-7.

Two staging systems for gastrointestinal stromal tumors in the stomach: which is better?

Chul Hong Park  1 , Gwang Ha Kim  2 , Bong Eun Lee  1 , Geun Am Song  1 , Do Youn Park  3 , Kyung Un Choi  3 , Dae Hwan Kim  4 , Tae Yong Jeon  4
Affiliations
Observational Study

Two staging systems for gastrointestinal stromal tumors in the stomach: which is better?

Chul Hong Park et al. BMC Gastroenterol. .

Abstract

Background: The prognosis of a gastrointestinal stromal tumor (GIST) is influenced by its anatomic site; however, few studies on the prognosis of gastric GISTs have been reported. The aims of this study were to evaluate long-term prognoses of patients who underwent surgical resection for gastric GISTs and to compare the clinical efficacy of two staging systems: the National Institutes of Health (NIH) consensus criteria and the 7th Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) tumor-node-metastasis (TNM) staging system.

Methods: We conducted a retrospective observational study of 145 patients who underwent surgical resection for gastric GISTs between February 2001 and June 2012 at Pusan National University Hospital (Busan, Korea). Recurrence and 5-year recurrence-free survival (RFS) rates were analyzed.

Results: During a median follow-up period of 44 months (range, 6-144 months), 11 recurrent lesions were detected in 9 patients (6.4%). On multivariate analysis, tumor size (>5 cm), mitotic count (>5/50 high-power fields), and epithelioid and mixed pathological type were significantly associated with recurrence. The overall 5-year RFS rate was 93.4%. Although no statistically significant differences were detected (C-statistic difference P = 0.886), all metrics showed lower values for the UICC/AJCC TNM staging system than for the NIH consensus criteria, suggesting that the UICC/AJCC TNM staging system may be a better model.

Conclusions: The 5-year RFS rate in patients who underwent curative resection for gastric GISTs was excellent. The UICC/AJCC TNM staging system may be more useful than the NIH consensus criteria for risk categorization of patients with gastric GISTs.

Keywords: Gastrointestinal stromal tumors; Prognosis; Recurrence; Staging; Stomach.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

The study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of Pusan National University Hospital (E-2015216).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Histologic subtypes of GISTs. a Spindle cell type. The tumor is composed of fusiform spindle cells with a fascicular growth pattern. b Epithelioid type. The tumor is composed of large round or polygonal cells with abundant, often eosinophilic or clear cytoplasm. c Mixed type. The tumor is composed of mixture of both types (hematoxylin and eosin staining, original magnification x400).
Fig. 2
Fig. 2
Recurrence-free survival rate of patients undergoing surgical resection for gastric GISTs according to the NIH consensus criteria
Fig. 3
Fig. 3
Recurrence-free survival rate of patients undergoing surgical resection for gastric GISTs according to the 7th UICC/AJCC TNM staging system
See this image and copyright information in PMC

References

    1. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577–580. doi: 10.1126/science.279.5350.577. - DOI - PubMed
    1. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459–465. doi: 10.1053/hupa.2002.123545. - DOI - PubMed
    1. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342–4349. doi: 10.1200/JCO.2003.04.190. - DOI - PubMed
    1. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23:70–83. doi: 10.1053/j.semdp.2006.09.001. - DOI - PubMed
    1. Sepe PS, Brugge WRA. Guide for the diagnosis and management of gastrointestinal stromal cell tumors. Nat Rev Gastroenterol Hepatol. 2009;6:363–371. doi: 10.1038/nrgastro.2009.43. - DOI - PubMed

Publication types

MeSH terms